

Trustee's report 31 December 2024

The Trustees present their report along with the accounts of the Friends of EORTC (the Charity) for the year ended 31 December 2024. The accounts have been prepared in accordance with the accounting policies set out on pages 16 to 18 and comply with the charity's trust deed, the Charities Act 2011 and 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Structure, governance and management

The Charity was established under a Trust Deed in 1976 and is registered with the Charity Commission under charity number 272818.

The Chairman, Comte Diego du Monceau de Bergendal, was appointed a trustee in 2015 on the retirement of the then Chairman, Sir Christopher Mallaby. His fellow trustee, Lady Solti was appointed a trustee in 1998, and Mr Edward Chandler was appointed on 7 October 2020, coinciding with the resignation of Mrs Victoria Agnew who had dedicated 22 years to her role with the organisation. Pr. Duncan Jodrell was appointed on 10 November 2021 to replace Lady Solti. Mrs Artis was appointed on 7 October 2022. Mr Edward Chandler resigned on March 1, 2023. There is no time limit on the tenure of the trustees. The trustees meet twice a year.

The Board keeps the skill requirements for the Trustee Body under review and if a trustee permanently retires or additional trustees are required, the Board would put in place appropriate procedures to recruit the new trustee(s). The Board would also ensure that appropriate induction and training is provided to all new trustees.

Statement of trustees' responsibilities

The trustees are responsible for preparing the trustees' report and accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare accounts for each fiscal year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Risk management

The Charity does not have any employees, significant contracts or material investments nor is the Charity dependent on grant funding from external sources to maintain its charitable activities. As a result of these limited activities, the Charity is exposed to few significant risks. The principal risk faced by the Charity would be the failure to generate sufficient donations to cover the costs of organising a fundraising event. This is mitigated by the Charity, wherever possible, by raising funds in advance of costs being incurred; carefully planning its fundraising events; targeting known supporters of the Charity and closely monitoring fundraising costs and donations.

Objectives and Activities

EORTC was set up in 1962 by leading cancer specialists in the EU and Switzerland in order that research on treatment of cancer could be co-ordinated and carried out on a European scale, thereby avoiding duplication and achieving economies of time and money.

The primary object of the Charity, as stated in its governing document, is to support the charitable objects and purposes of EORTC Cancer Research Fund AISBL (ECRF), a charity registered in Belgium. The ECRF was established in 1976, as The EORTC Foundation. This charitable trust was established to support the activities of the EORTC.

The ECRF supports the activities of the EORTC through annual grant payments to the EORTC which are used by the EORTC to fund research into cancer treatments. The Friends of EORTC supports the ECRF by organising fundraising events in the UK and by a major fundraising initiative. The funds raised by the Friends of EORTC are then used to support the activities of the ECRF. The Friends of EORTC makes donations to EORTC on an ad-hoc basis, as determined by the Trustees.

Achievements and Performance

Financial review

The income of the charity declined over that of the previous year, however the major fundraising initiative continued, and national and private donations were received in 2024. The charity received donations from its supporters amounting to £40,857 (2023 - £77,102).

Total expenditure: £ 40,857 (2023 - £ 77,102).

The charity remains financially stable with a small loss.

Interest and foreign exchange

The Charity earned £557 in interest in 2024 (2023 – £1,199) and booked no foreign exchange gains (2023 – none).

Walgreen's Boots Alliance

EORTC Cancer Research Fund (formerly the EORTC Charitable Trust) has been in partnership with Walgreens Alliance Boots (WBA, then Alliance Boots) since late 2011. The partnership focused on creating the first pan-European biobank in advanced colorectal cancer, now fully operational in Dresden. WBA committed to raising €5 million over five years to support this key research infrastructure. Scientific planning for the project, named SPECTAcOLOR, began in 2012 with the development of biobanking facilities and identification of participating hospitals.

The success of SPECTAcOLOR led EORTC to expand to other cancer types, culminating in 2018 with the launch of SPECTA, a unified platform for all cancers, including rare ones, with a central biobank in Luxembourg. That same year, WBA renewed its support through a new €5 million, five-year agreement, reaffirming SPECTA's position as a leading translational research infrastructure.

In October 2022, WBA and EORTC launched a new three-year fundraising effort to raise €1.8 million for the OligoRARE study and the E²-RADlatE platform, which aims to define optimal radiation therapy practices for future clinical standards.

E²-RADlatE is the only pan-European platform dedicated to radiation oncology research, integrating clinical data with diagnostic imaging, treatment data, economic outcomes, and patient-reported experiences to enhance patient-centred care.

The platform includes several observational cohort studies and clinical trials:

- **OligoCare** (EORTC 1822-RP): the first activated cohort, focuses on patients with oligometastatic disease (cancer spread to a limited number of organs), aiming to identify factors influencing survival after radical radiotherapy. Cancer types studied include breast, lung, prostate, and colorectal.

- **ReCare** (EORTC 2011-RP): collects real-world data on high-dose re-irradiation in cases of recurrence or secondary cancers. It aims to provide evidence on efficacy and safety of re-treatment in the modern radiotherapy era.
- **OligoRARE** (EORTC 1945): a randomized clinical trial evaluating whether SABR (Stereotactic Ablative Body Radiotherapy) improves survival compared to standard care in patients with oligometastatic rare cancers.
- **SPRINT** (EORTC 2387): is the first pan-European Trial within Cohorts (TwICs), leveraging real-world data from the OligoCare cohort to evaluate treatment strategies for patients with oligometastatic breast, prostate, lung, and colorectal cancers. The study aims to determine whether a single fraction of stereotactic body radiotherapy (SBRT) can be as effective as multi-fraction SBRT, potentially reducing treatment burden while improving patient experience and quality of life.

E²-RADlatE supports radiotherapy's role as a cornerstone of cancer care, used by half of all patients during treatment. By leveraging advanced technology and structured data collection, the platform contributes to reducing inequities in care and improving outcomes across Europe.

Alliance Healthcare (to be renamed Cencora)

In June 2021, Walgreens Boots Alliance sold its Alliance Healthcare businesses to AmerisourceBergen, now renamed Cencora. Alliance Healthcare, now a wholly owned subsidiary of Cencora, supported the SPECTA platform under its new ownership with half of the initial pledge be raised by the end of the agreement in 2023. In 2024, Cencora contributed an additional \$100K towards the platform. The funds raised through the partnership are estimated to cover the current activities of the platform until 2027.

Alliance Healthcare (soon to be renamed Cencora) contributions

From June 1st, 2021, to December 2024, 2023, Alliance Healthcare has raised a total of €2,192,401.24.

AMRC - Association of Medical Research Charities

Since October 2014, the Friends of EORTC has been a member of AMRC. This membership provides clear benefits for EORTC and for the costs related to its international clinical studies being opened or adopted in the UK. Membership of AMRC helps the EORTC to qualify as eligible under the UK NHS AcoRD Programme under which certain clinical research costs are met by the National Health Service.

Under AcoRD, AMRC charities that fund in open competition do not have to pay these costs. The work will be done by the NIHR Clinical Research Networks or will be covered by the infrastructure support funding going to NHS trusts and universities. EORTC, through the Friends of EORTC, is in good standing for support from the NIHR and NHS for other study related costs as described above.

UK Liaison Office

A Liaison Office has been established in the UK between the National Cancer Research Institute (NCRI), EORTC and CR-UK to promote better communications between these three organisations and to facilitate the adoption of EORTC's international studies in the UK and the extension of UK studies into Europe. The Friends of EORTC supports this initiative by currently contributing one third of the costs of the salary of the Liaison Officer, based at the University of Leeds. Since 2017, the costs of the Liaison Office in Leeds have been shared between EORTC and CR-UK.

Investment powers, policy, and performance

The Charity does not hold investments other than cash held on an interest bearing deposit on a short-term basis. These funds are held in the Charity's bank account, held by Coutts.

Grant making policy

The Charity makes grants to the EORTC and to the EORTC Cancer Research Fund and for fellowships, as direct grants or on an ad-hoc basis.

Reserves

The Charity makes grants to the EORTC as cash becomes available, retaining sufficient funds to cover the potential outgoings associated with future fundraising events. The Charity does not enter on-going commitments and therefore does not need to ensure a steady flow of income. For this reason, the trustees do not consider it appropriate to maintain a target level of reserves.

The funds raised by the Charity are held as deposits on call accounts until such time that the Trustees wish to make grants or donations directly to the EORTC to support their ongoing activities.

Going concern

The Trustees of the charity have determined that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion, based on available information at the date of approval of the financial statements, that the charity will have sufficient resources to meet its liabilities as they fall due. They do not believe that there are concerns regarding the charity's ability to continue as a going concern.

EXPENSES		Act 2018	Act 2019	Act 2020	Act 2021	Act 2022	Act 2023	Jan-24	Feb-24	Mar-24	Apr-24	May-24	ACT 2024
LO	Liaison Office Leeds	34,798	39,442	34,456	42,674	41,700	42,273			11,708.33	-11,708.33		32,899.26
	Liaison Office Leeds VAT (non ded 20%)												6,579.85
	Liaison Office Leeds corr		-8,521	-6,574	0	-7,112	-8,340						0.00
	TOTAL	34,798	30,921	27,882	42,674	34,587	33,933	0	0	11,708	-11,708	0	39,479.11
ADMIN	Accounting												
	Audit (#613110)	3,060	3,150	3,330	3,480	3,960	4,200			1,102.50	-1,102.50		0.00
	Audit (regul. Y-1)		210	0	120	-12	0						0.00
	Chartered accountant												1,200.00
	Consultancy	0	0	0	0	0	0						0.00
	Subscriptions (AMRC)	446.90	548	552	803	1,126	665	52.08	52.08	52.12	41.67	41.67	531.31
	Monthly fee (just-giving)	216.00	216	216	216	162	216	18.00	18.00	18.00	18.00	18.00	216.00
	Insurances	0.00	0	0	0	0	0						0.00
TOTAL		3,723	4,124	4,098	4,619	5,236	5,081	70	70	1,173	-1,043	60	1,947.31
Expenditure EORTC CRF		0	0	0	0	0	0						0.00
Gift Aid cancellation		0	0	0	0	0	3,700						0.00
Expenditure EORTC HQ Core Grant		0	0	0	0	0	0						0.00
Transfer EORTC (WBA): SPECTA		0	1,158,496	129,538	161,837	0	0						0.00
Transfer EORTC (AmerisourceBergen): SPECTA					46,070	154,949	1						36.25
Transfer EORTC (WBA): E2-RADiate						0	33,821					33,821	0.00
Transfer China Challenge					3,713	7,842	0						0.00
Transfer EORTC (ECRF 40th anniv.)			218,496	0	0	0	0						0.00
Transfer EORTC (EORTC 60th anniv.)						1,500	0						0.00
Transfer Strass II						25,000	0						0.00
Grant Snowman		0	0	0	0	33,872	0						0.00
Grant Grierson		0	0	0	0	27,739	0						0.00
Bank charges		789	744	470	756	642	559			121.75		70.00	590.60
Currency exchange		94	0	0	18	8	0						0.00
Other financial charges (Justgiving)		15	462	65	90	9	7					0.36	4.02
Other financial charges (Ammado/Stripe)		0	0	0	0	8	0						0.00
TOTAL COSTS		39,419	1,413,243	162,052	259,776	291,392	77,103	70	70	13,003	-12,751	33,951	42,057.29

FRIENDS OF EORTC

Income statement (GBP) - December 30, 2024

INCOME		Act 2020	Act 2021	Act 2022	Act 2023	Act 2024	EXPENSES	Act 2020	Act 2021	Act 2022	Act 2023	Act 2024
Liaison Office Leeds (EORTC)		27,882	42,674	34,587	33,933	39,479	Liaison Office Leeds	27,882	42,674	34,587	33,933	39,479
Unrestricted donations	Others (Stripe, Justgiving,...)	156	326	498	20	50	Administration	4,098	4,619	5,236	5,081	1,947
	ECRF 40th anniversary						Gifi Aid				3,700	
	EORTC 60th anniversary			1,500	0	0	Transfer EORTC		3,713	1,500		0
Restricted donations	Grierson					0	Grierson			33,872		0
	Snowman					0	Snowman			27,739		0
Mc Millan	GWOC China Challenge	19,339	5,184				GWOC China Challenge			7,842		0
WBA	CSR Programs 1& 2/1	129,599	161,884				SPECTA (WBA)	129,538	161,837			0
Cencora (AmerisourceBergen)	CSR Program 2/2		46,112	154,958	284	36	SPECTA (Cencora)		46,070	154,949	1	36
WBA	E2-Radiate				33,544	0	E2-RADiate (WBA)				33,821	0
Climbers Against Cancer	Strass II (1809)			25,000		0	Strass II (CAC)			25,000		0
Financials income		125	26	203	1,199	557	Financial costs	534	864	668	566	595
TOTAL REVENUE		177,101	256,206	216,745	68,980	40,123	TOTAL COSTS	162,052	259,776	291,392	77,103	42,057
		0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00	0.00	0.00
Surplus of the year (+) / (-)		15,049	-3,570	-74,647	-8,123	-1,935						

FRIENDS OF EORTC

Income Statement

December 31, 2024

in GBP

	Act 2020	Act 2021	Act 2022	Act 2023
I. Operating Income (A+B+C)	176,976	256,180	216,543	64,081
A. Turnover	176,976	256,180	216,543	64,081
A1. Unrestricted contributions				
A2. Unrestricted donations	156	326	1,998	-3,680
A3. Restricted donations	176,820	255,854	214,545	67,761
B. Other operating income	0	0	0	0
II. Operating Charges (A+B+C+D)	-161,518	-258,912	-290,725	-72,837
A. Services and other goods	-31,980	-47,293	-39,823	-39,014
Offices				
Administration	-4,098	-4,619	-5,236	-5,081
Liaison Office Leeds (EORTC)	-27,882	-42,674	-34,587	-33,933
D. Other operating charges	-129,538	-211,619	-250,902	-33,823
III. Operating result (I - II)	15,458	-2,732	-74,182	-8,756
IV. Financial result	-409	-838	-465	633
VI. Profit for the period (III - IV - V)	15,049	-3,570	-74,647	-8,123

Friends of EORTC - Income statement

December 31, 2024

in GBP

	2021	2022	2023
I OPERATING INCOME	256,180	216,543	64,081
Unrestricted donations	326	1,998	-3,680
Restricted donations	213,179	179,958	33,828
Liaison Office Leeds (EORTC)	42,674	34,587	33,933
II OPERATING CHARGES	-258,912	-290,725	-72,837
Offices			
Administration	-4,619	-5,236	-5,081
Travel			
Liaison Office Leeds (EORTC)	-42,674	-34,587	-33,933
Transfert to EORTC	-211,619	-250,902	-33,823
III OPERATING PROFIT (I + II)	-2,732	-74,182	-8,756
IV-V Financial result	-838	-465	633
VI Surplus/Loss for the period (before taxes)	-3,570	-74,647	-8,123
VII Surplus/Loss for the period (after taxes)	-3,570	-74,647	-8,123

2024

39,565

50

36

39,479

-41,463

-1,947

-39,479

-36

-1,897

-37

-1,935

-1,935

December 31, 2024

in GBP

	Act 2018	Act 2019	Act 2020	Act 2021	Act 2022
ASSETS					
FIXED ASSETS	0	0	0	0	0
II. Intangible assets					
III. Tangible assets					
IV. Financial assets (Rent deposit)					
CURRENT ASSETS	591,241	134,209	277,661	356,884	238,349
VII. Amounts receivable < 1 year					
VIII. Investments - savings					
IX. Cash at bank and in hand	552,682	90,970	239,414	310,367	184,413
Coutts (GBP) - current account	750	750	750	750	750
Coutts (GBP) - business account	551,932	90,220	238,664	309,617	183,663
X. Deferred charges and accrued income	38,559	43,239	38,247	46,516	53,936
TOTAL	591,241	134,209	277,661	356,884	238,349
LIABILITIES					
EQUITY	550,352	91,069	106,117	102,547	27,900
I. Association funds					
IV. Restricted funds - WBA	241,851				
IV. Restricted funds - Snowman (Fellowship)	33,872	33,872	33,872	33,872	
IV. Restricted funds - Grierson (Fellowship)	27,739	27,739	27,739	27,739	
IV. Restricted funds - ECRF 40th anniversary	218,496				
V. Surplus (loss) carried forward	28,395	29,458	44,506	40,936	27,900
Surplus (loss) of the period					
CREDITORS	40,889	43,140	171,544	254,337	210,449
IX. Amounts payable < 1 year	26,276	0	3,804	234	0
A. Financial debts					
B. Trade debts	26,276	0	3,804	234	0
C. Advances received on contracts in progress					
D. Taxes, remuneration and social security					
E. Other amounts payable					
X. Accrued charges and deferred income	14,612	43,140	167,740	254,103	210,449
TOTAL	591,241	134,209	277,661	356,884	238,349

FRIENDS OF EORTC- Balance sheet statement

December 31, 2024

in GBP

ASSETS	2023	2024		
FIXED ASSETS	0	0	0	
II. Intangible assets	0	0	0	I.
III. Tangible assets	0	0	0	IV.
A. Plant, machinery and equipment	0	0	0	IV.
B. Furniture	0	0	0	IV.
C. Assets under constructions and advance	0	0	0	IV.
IV. Financial assets (Rent deposit)	0	0	0	V.
				V.
CURRENT ASSETS	100,913	49,797	-51,116	
				IX.
VII. Amounts receivable < 1 year	0	0		
E. Trade debtors	0	0		
F. Other amounts receivable	0	0		
VIII. Investments	0	0		
IX. Cash at bank and in hand	58,483	18,955	-39,528	
X. Deferred charges and accrued income	42,429	30,842	-11,587	X.
TOTAL ASSETS	100,913	49,797		
Var. (Y/Y-1)				
		0.82886		

LIABILITIES**2023 2024****EQUITY****19,777 17,842 -1,935**

Association funds

0

Restricted funds - WBA

0

Restricted funds - Gillings Foundation

0

Restricted funds - Snowman (Fellowship)

0

Restricted funds - Grierson (Fellowship)

0

Surplus (loss) carried forward

19,777

19,777

-1,935

Surplus (loss) of the period

-1,935

CREDITORS**81,135 31,955 -49,181**

Amounts payable < 1 year

47,313

30,717

-16,596

A. Financial debts

0

B. Trade debts

47,313

30,717

-16,596

C. Advance payments on contracts in progress

0

D. Taxes, remuneration and social security

0

E. Other amounts payable

0

0

0

Accruals and deferred income

33,823

1,238

-32,585

TOTAL LIABILITIES**100,913****49,797**

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Fee	2,550.00	2,550.00	2,625.00	2,700.00	2,800.00	2,890.00	3,300.00	3,500.00	
VAT	<u>510.00</u>	<u>510.00</u>	<u>525.00</u>	<u>540.00</u>	<u>560.00</u>	<u>578.00</u>	<u>660.00</u>	<u>700.00</u>	
	3,060.00	3,060.00	3,150.00	3,240.00	3,360.00	3,468.00	3,960.00	4,200.00	0.00
		0.0%	2.9%	2.9%	3.7%	3.2%	14.2%	6.1%	-100.0%

	A6		A7	A7	
From	4/1/2023	From	4/1/2024	4/1/2025	
To	3/31/2024	To	3/31/2025	3/31/2026	
Gross salary 1.5 FTE	47,340	Gross salary	45,148	46,503	91,651
				3.0%	
Overheads and Non Pay	17,406	Overheads and Non Pay	13,287	13,626	26,913
	36.8%		29.4%	29.3%	29.4%
Pension/NI contribution	14,283	Pension/NI contribution	11,747	12,138	23,885
	30.2%		26.0%	26.1%	26.1%
TOTAL	79,029	TOTAL	70,182	72,267	142,449
Contributions		Contributions			
Leeds	47,417	Leeds 40%	28,073	28,907	56,980
	60.0%	EORTC 60%	<u>42,109</u>	<u>43,360</u>	85,469
EORTC	31,612		70,182	72,267	142,449
	40.0%				
2024	7,903.00	2024	31,581.90		
Invoiced	7,301.81	Invoiced	25,597.47		

Overheads and non-pay costs mentioned in the table above should include/cover all extra costs associated with performing EORTC Liaison Office activities such as local office infrastructure (incl. office materials & equipment, IT support) and meetings travels costs related to performing of both LOs function (i.e., EGAM attendance, attendance to CRUK-NCRI-EORTC biannual meeting).

Subscripti Expenditures

Act 2018	446.90	38,520.50	1.16%
Act 2019	548.01	35,044.87	1.56%
Act 2020	551.81	31,979.60	1.73%
Act 2021	802.94	47,293.04	1.70%
Act 2022	1,125.65	39,823.06	2.83%
Act 2023	665.42	39,014.40	1.71%
Act 2024	665.42	40,226.42	1.65%

Please note that although fees are not being raised this year if your spend on research in 2024-5 has taken you into a higher or lower bracket you won't be charged the same amount next year. To help you with your budgeting I have included the bandings here – these figures include all member benefits including events.

Band	UK research expenditure	2024-5 subscription fee
1	>£40,000,000	Capped
2	£25,000,000 - £39,999,999	Capped
3	£12,500,000 - £24,999,999	£33,645
4	£7,500,000 - £12,499,999	£18,325
5	£5,000,000 - £7,499,999	£11,745
6	£3,750,000 - £4,999,999	£8,435
7	£2,500,000 - £3,749,999	£6,160
8	£1,500,000 - £2,499,999	£4,305
9	£850,000 - £1,499,999	£2,660
10	£650,000 - £849,999	£1,715
11	£450,000 - £649,999	£1,215
12	£350,000 - £449,999	£850
13	£250,000 - £349,999	£625
14	£0 - £249,999	£500

If you have any questions, please do not hesitate to get in touch.

Independent examiner's report to the trustees of the Friends of EORTC

I report to the trustees on my examination of the accounts of the Friends of EORTC for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Name: Melissa Foux

Relevant professional qualification or membership of professional bodies (if any):

Chartered Accountant ICAEW Membership number 8313878

Address: 56 Flanders Road London W4 1NG

Date: 11/10/2025